Publications (58) EDUARDO VILLACORTA ARGÜELLES publications

filter_list

2025

  1. Hereditary transthyretin amyloidosis caused by the Val142Ile variant in Spain

    Revista Espanola de Cardiologia

  2. Left ventricular ejection fraction decline and cardiovascular events in suspected cardiomyopathy with excessive trabeculation: toward precision medicine

    Revista Espanola de Cardiologia

  3. Prevalence of Cardiac Amyloidosis Among Elderly Patients With Recent-Onset Atrial Fibrillation: The PREVAL-ATTR Study

    Canadian Journal of Cardiology, Vol. 41, Núm. 2, pp. 167-177

2024

  1. Characterization of the plasma proteomic profile of Fabry disease: Potential sex- and clinical phenotype-specific biomarkers

    Translational Research, Vol. 269, pp. 47-63

  2. Endomyocardial biopsy: safety and prognostic utility in paediatric and adult myocarditis in the European Society of Cardiology EURObservational Research Programme Cardiomyopathy and Myocarditis Long-Term Registry

    European Heart Journal, Vol. 45, Núm. 28, pp. 2548-2569

  3. Intermediate-effect size p.Arg637Gln in FHOD3 increases risk of HCM and is associated with an aggressive phenotype in homozygous carriers

    Journal of Medical Genetics, Vol. 61, Núm. 5, pp. 423-427

  4. Pacientes riesgo de endocarditis infecciosa: prevención y educación

    45 Congreso Nacional de la SEMI - 19 Congreso de la Sociedad Canaria de Medicina Interna

  5. Penetrance of Dilated Cardiomyopathy in Genotype-Positive Relatives

    Journal of the American College of Cardiology, Vol. 83, Núm. 17, pp. 1640-1651

  6. Rare Genetic Variants in Young Adults Requiring Pacemaker Implantation

    JACC: Clinical Electrophysiology, Vol. 10, Núm. 10, pp. 2250-2260

  7. Variable Penetrance and Expressivity of a Rare Pore Loss-of-Function Mutation (p.L889V) of Nav1.5 Channels in Three Spanish Families

    International Journal of Molecular Sciences, Vol. 25, Núm. 9

2023

  1. Association between common cardiovascular risk factors and clinical phenotype in patients with hypertrophic cardiomyopathy from the European Society of Cardiology (ESC) EurObservational Research Programme (EORP) Cardiomyopathy/Myocarditis registry

    European Heart Journal - Quality of Care and Clinical Outcomes, Vol. 9, Núm. 1, pp. 42-53

  2. Burden of untreated transthyretin amyloid cardiomyopathy on patients and their caregivers by disease severity: results from a multicenter, non-interventional, real-world study

    Frontiers in Cardiovascular Medicine, Vol. 10

  3. Heart failure in a patient with multiple myeloma

    REC: CardioClinics, Vol. 58, Núm. 4, pp. 333-334

  4. Importance of genetic study in elderly patients with transthyretin cardiac amyloidosis

    Medicina Clinica, Vol. 161, Núm. 9, pp. 382-385

  5. Late gadolinium enhancement distribution patterns in non-ischaemic dilated cardiomyopathy: genotype-phenotype correlation

    European heart journal. Cardiovascular Imaging, Vol. 25, Núm. 1, pp. 75-85

  6. Selection of the best of 2022 in familial heart disease and cardiovascular genetics

    REC: CardioClinics, Vol. 58, pp. S68-S73

  7. Unravelling an hypertrophic myocardiopathy

    European heart journal, Vol. 44, Núm. 29, pp. 2788

2022

  1. Combination of late gadolinium enhancement and genotype improves prediction of prognosis in non-ischaemic dilated cardiomyopathy

    European Journal of Heart Failure, Vol. 24, Núm. 7, pp. 1183-1196

  2. Drug-eluting stents and contemporary dual antiplatelet therapy in revascularized STEMI. The times they are a-changin’?

    Revista Espanola de Cardiologia, Vol. 75, Núm. 8, pp. 623-625

  3. Impact of SARS-Cov-2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry

    ESC Heart Failure, Vol. 9, Núm. 4, pp. 2189-2198